This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Acadia Healthcare (ACHC) Tops Q4 Earnings, Gives 2017 View
by Zacks Equity Research
Acadia Healthcare Company Inc. (ACHC) reported fourth-quarter 2016 adjusted earnings of 59 cents per share, which surpassed the Zacks Consensus Estimate by 4 cents.
Abbott Laboratories Gains Despite Unimpressive Q4 Revenue Results
by Parth Panchal
Abbott Laboratories (ABT) just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion.
Abbott Labs (ABT) Tops Q4 Earnings Estimates, Sales In Line
by Zacks Equity Research
Abbott Laboratories (ABT) reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate.
Abbott Laboratories (ABT): Tops Q4 Earnings, Sales in Line
by Zacks Equity Research
Abbott Laboratories (ABT) earnings per share has beaten the Zacks Consensus Estimated while its revenues were almost in line with the mar.
3 Stocks with Great Earnings Charts
by Tracey Ryniec
Looking for stocks that beat on earnings nearly every quarter?
What's in Store for Abbott Labs (ABT) This Earnings Season?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.
IDEXX Laboratories (IDXX) Set to Join the S&P 500 Index
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is scheduled to join the coveted S&P 500 benchmark, after the market closes on Jan 4.
Abbott Labs to Close St. Jude Acquisition Later this Week
by Zacks Equity Research
Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.
AbbVie's Humira and Imbruvica Drive Performance in 2016
by Zacks Equity Research
AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.
Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout
by Zacks Equity Research
Abbott Laboratories (ABT) has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical (STJ).
Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs
by Zacks Equity Research
Mylan (MYL) has revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on integrating acquisitions.
Q3 Earnings Continue, Housing and Permits Mixed
by Mark Vickery
Housing starts fell 9% but building permits rose 6.3%. We also see earnings results from Morgan Stanley, U.S. Bancorp, Abbott Labs, Halliburton and Seagate.
Q2 Earnings Season Coming Up Roses
by Mark Vickery
Morgan Stanley, Abbott Labs and Halliburton all beat earnings expectations before the opening bell today.
Bear of the Day: AbbVie (ABBV)
by Kevin Cook
Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus
Parade of Mixed Earnings
by Sheraz Mian
Stocks have made solid gains in recent sessions, pushing the S&P 500 index above the 2100 level.
Bear of the Day: Abbott Labs (ABT)
by Eric Dutram
This stock could infect your portfolio thanks to its sluggish outlook and crumbling earnings estimates.